Thrombolysis in newborns and infants.

摘要: This review analyses literature reports from 1970 to 1998 assessing the use of streptokinase (SK), urokinase (UK) or recombinant tissue-type plasminogen activator (rt-PA) for thrombolytic therapy in neonates and infants. From 182 infants were reported have received SK (n = 54; 29.5%), UK 41; 22.5%) rt-PA 87; 48%). During no concomitant heparin administration low dose (5 U/kg/h) recorded. To perform reocclusion prophylactics was reinitiated at end usually recommended dosage 20 U/ kg/h. The overall patency rate varied 39% 86%. Besides bleeding local puncture sites recent catheterisation (10.4%), pulmonary embolism 1.1% Major complications, i.e. (0.6%), gastrointestinal (0.6%) intraventricular haemorrhage (IVH 2.7%) are rarely side effects only 2 thrombolysis related deaths due mentioned. Bleedings central nervous system 4) mainly occurred preterm 3). In conclusion, data this preliminary analysis suggest that there is big difference (p 0.09; chi2-test) efficacy between 3 agents used first year life. each case an assessment must be made with respect relative benefit conferred by preventing organ limb damage versus potential effects, costs inconvenience childhood patient. Controlled prospective multicentre studies on evaluate rates adverse different used.